Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $114 from $86 and keeps a Buy rating on the shares after the company reported “very impressive” Q2 earnings last month. The firm continues to see ANI Pharmaceuticals as “uniquely positioned” to deliver fundamental upside driven by the firm’s strengthened bullish view on Cortrophin Gel, while also being “relatively immune” to many of the macro uncertainties that are impacting the broader biopharma segment, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Highlights Commercialization Focus Amid Challenges
- ANI Pharmaceuticals’ Record Earnings and Optimistic Outlook
- ANI Pharmaceuticals price target raised to $77 from $65 at Truist
- ANI Pharmaceuticals Reports Record Growth in Q2 2025
- ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright